Quantum Biopharma Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filerEmerging growth company
State of Incorporation
Ontario, Canada
Country
Ontario, Canada
Business Address
55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, , M5J 2H7
Mailing Address
55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, , M5J 2H7
Phone
(416) 854-8884
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 2, 2026 | View on SEC |
| 6-K Foreign company current report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | March 27, 2026 | View on SEC |
| 20-F Foreign company annual report | March 26, 2026 | View on SEC |
| 6-K Foreign company current report | March 26, 2026 | View on SEC |
| 6-K Foreign company current report | March 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 3, 2026 | View on SEC |
| 6-K Foreign company current report | December 23, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 22, 2025 | View on SEC |
Annual Reports
20-F
March 26, 2026
- Advancing Lucid-MS drug candidate toward Phase 2 human trials by late 2025.
- Transitioned Unbuzzd™ functional beverage to a licensing model to reduce overhead.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.